265 related articles for article (PubMed ID: 12835546)
1. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study.
Thaçi D; Steinmeyer K; Ebelin ME; Scott G; Kaufmann R
Dermatology; 2003; 207(1):37-42. PubMed ID: 12835546
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
Ling M; Gottlieb A; Pariser D; Caro I; Stewart D; Scott G; Abrams K
J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
[TBL] [Abstract][Full Text] [Related]
3. Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis.
Van Leent EJ; Ebelin ME; Burtin P; Dorobek B; Spuls PI; Bos JD
Dermatology; 2002; 204(1):63-8. PubMed ID: 11834853
[TBL] [Abstract][Full Text] [Related]
4. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis--a multicenter, 3-week, open-label study.
Staab D; Pariser D; Gottlieb AB; Kaufmann R; Eichenfield LF; Langley RG; Scott G; Ebelin ME; Barilla D; Schmidli H; Burtin P
Pediatr Dermatol; 2005; 22(5):465-71. PubMed ID: 16191004
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice.
Lübbe J; Friedlander SF; Cribier B; Morren MA; García-Díez A; Gelmetti C; Hofmann H; Houwing RH; Kownacki S; Langley RG; Virtanen M; Wolff K; Wisseh S; McGeown C; Abrams B; Schneider D;
Am J Clin Dermatol; 2006; 7(2):121-31. PubMed ID: 16605292
[TBL] [Abstract][Full Text] [Related]
7. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis.
Wellington K; Jarvis B
Drugs; 2002; 62(5):817-40. PubMed ID: 11929333
[TBL] [Abstract][Full Text] [Related]
8. Blood concentrations of pimecrolimus in adult patients with atopic dermatitis following intermittent administration of pimecrolimus cream 1% (Elidel) for up to 1 year.
Van Leent EJ; De Vries HJ; Ebelin ME; Burtin P; Scott G; Bos JD
J Dermatolog Treat; 2007; 18(1):19-22. PubMed ID: 17365262
[TBL] [Abstract][Full Text] [Related]
9. Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis.
Belsito DV; Fowler JF; Marks JG; Pariser DM; Hanifin J; Duarte IA; Pires MC; Cruz PD; Langley RG; Patel P; Bush C; Thurston M; Graeber M; Cherill R;
Cutis; 2004 Jan; 73(1):31-8. PubMed ID: 14964629
[TBL] [Abstract][Full Text] [Related]
10. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study.
Meurer M; Fölster-Holst R; Wozel G; Weidinger G; Jünger M; Bräutigam M;
Dermatology; 2002; 205(3):271-7. PubMed ID: 12399676
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on topical pimecrolimus in atopic dermatitis.
Wellington K; Jarvis B
Am J Clin Dermatol; 2002; 3(6):435-8. PubMed ID: 12113651
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of pimecrolimus 1% cream in the long term management of atopic hand dermatitis. A double-blind RCT.
Bauer A; Lange N; Matterne U; Meurer M; Braeutigam M; Diepgen TL
J Dtsch Dermatol Ges; 2012 Jun; 10(6):426-33. PubMed ID: 22112014
[TBL] [Abstract][Full Text] [Related]
13. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients.
Allen BR; Lakhanpaul M; Morris A; Lateo S; Davies T; Scott G; Cardno M; Ebelin ME; Burtin P; Stephenson TJ
Arch Dis Child; 2003 Nov; 88(11):969-73. PubMed ID: 14612358
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
[TBL] [Abstract][Full Text] [Related]
15. Pimecrolimus: a review.
Gupta AK; Chow M
J Eur Acad Dermatol Venereol; 2003 Sep; 17(5):493-503. PubMed ID: 12941081
[TBL] [Abstract][Full Text] [Related]
16. Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial.
Kaufmann R; Bieber T; Helgesen AL; Andersen BL; Luger T; Poulin Y; Al-Hafidh J; Paul C;
Allergy; 2006 Mar; 61(3):375-81. PubMed ID: 16436149
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis.
Van Leent EJ; Gräber M; Thurston M; Wagenaar A; Spuls PI; Bos JD
Arch Dermatol; 1998 Jul; 134(7):805-9. PubMed ID: 9681343
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents.
Eichenfield LF; Lucky AW; Boguniewicz M; Langley RG; Cherill R; Marshall K; Bush C; Graeber M
J Am Acad Dermatol; 2002 Apr; 46(4):495-504. PubMed ID: 11907497
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis.
Luger TA; Lahfa M; Fölster-Holst R; Gulliver WP; Allen R; Molloy S; Barbier N; Paul C; Bos JD
J Dermatolog Treat; 2004 Jun; 15(3):169-78. PubMed ID: 15204150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
